|Use||hypertriglyceridemia and hypercholesterolaemia|
In pharmacology, the fibrates are a class of amphipathic carboxylic acids. They are used for a range of metabolic disorders, mainly hypercholesterolemia (high cholesterol), and are therefore hypolipidemic agents.
Fibrates are used in accessory therapy in many forms of hypercholesterolemia, but are absolutely contraindicated in combination with statins due to an increased risk of rhabdomyolysis. These stimulate peroxisome proliferator activated receptor (PPAR) alpha, which controls the expression of gene products that mediate the metabolism of TG and HDL. As a result, synthesis of fatty acids, TG and VLDL is reduced, whilst that of lipoprotein lipase, which catabolises TG, is enhanced. In addition, production of Apo A1 and ATP binding cassette A1 is up-regulated, leading to increased reverse cholesterol transport via HDL. Consequently, fibrates reduce TG by up to 50% and increase HDL-C by up to 20%, but LDL-C changes are variable. Fewer large-scale trials have been conducted with fibrates than with statins and the results are less conclusive, but reduced rates of cardiovascular disease have been reported with fibrate therapy in the subgroup of patients with low HDL-C levels and elevated TG (e.g. TG > 2.3 mmol/L (200 mg/dL)). Fibrates are usually well tolerated but share a similar side-effect profile to statins. In addition, they may increase the risk of cholelithiasis and prolong the action of anticoagulants. Accumulating evidence suggests that they may also have a protective effect against diabetic microvascular complications.
Clinical trials do support their use as monotherapy agents. Fibrates reduce the number of non-fatal heart attacks, but do not improve all-cause mortality and are therefore indicated only in those not tolerant to statins.
Although less effective in lowering LDL levels, the ability of fibrates to increase HDL and lower triglyceride levels seems to reduce insulin resistance when the dyslipidemia is associated with other features of the metabolic syndrome (hypertension and diabetes mellitus type 2). They are therefore used in many hyperlipidemias. Due to a rare paradoxical decrease in HDL-C seen in some patients on fenofibrate, as per US FDA label change, it is recommended that the HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline.
Most fibrates can cause mild stomach upset and myopathy (muscle pain with CPK elevations). Fibrates decrease the synthesis of bile acid by down-regulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase expression, therefore making it easier for cholesterol to precipitate and increasing the risk for gallstones.
In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to kidney failure. The less lipophilic statins are less prone to cause this reaction, and are probably safer to be combined with fibrates than the more lipophilic statins are.
Although used clinically since the 1930s,[failed verification] if not earlier, the mechanism of action of fibrates remained unelucidated until, in the 1990s, it was discovered that fibrates activate PPAR (peroxisome proliferator-activated receptors), especially PPARα. The PPARs are a class of intracellular receptors that modulate carbohydrate and fat metabolism and adipose tissue differentiation.
Fibrates have been shown to extend lifespan in the roundworm C. elegans.
- Steiner G (December 2007). "Atherosclerosis in type 2 diabetes: a role for fibrate therapy?". Diabetes & Vascular Disease Research. 4 (4): 368–74. doi:10.3132/dvdr.2007.067. PMID 18158710.
- Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, et al. (October 2009). "Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review". The American Journal of Medicine. 122 (10): 962.e1–8. doi:10.1016/j.amjmed.2009.03.030. PMID 19698935.
- Jun M, Foote C, Lv J, et al. (2010). "Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis". Lancet. 375 (9729): 1875–1884. doi:10.1016/S0140-6736(10)60656-3. PMID 20462635.
- Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M (November 2016). Cochrane Heart Group (ed.). "Fibrates for primary prevention of cardiovascular disease events". The Cochrane Database of Systematic Reviews. 11: CD009753. doi:10.1002/14651858.CD009753.pub2. PMC 6464497. PMID 27849333.
- Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z (April 2004). "Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome". International Journal of Clinical Pharmacology and Therapeutics. 42 (4): 212–7. doi:10.5414/cpp42212. PMID 15124979.
- Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, et al. (April 2012). "New fibrate use and acute renal outcomes in elderly adults: a population-based study". Annals of Internal Medicine. 156 (8): 560–9. doi:10.7326/0003-4819-156-8-201204170-00003. PMID 22508733.
- "Pharmaceutical composition and method for treatment of digestive disorders - Patent 4976970". Retrieved 2008-12-20.
- Lee, T.K. "Fibrates in Perspective: Answering an Age-Old Question" (PDF). Perspectives in Cardiology. 20 (6): 34–39.
- Brandstädt, Sven; Schmeisser, Kathrin; Zarse, Kim; Ristow, Michael (2013-04-08). "Lipid-lowering fibrates extend C. elegans lifespan in a NHR-49/PPARalpha-dependent manner". Aging. 5 (4): 270–275. doi:10.18632/aging.100548.